Venetoclax Plus Dose-adjusted EPOCH-R for Richter's Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.
- 20 Feb 2017 New trial record